Selective inhibitors of DYRK1A have been extensively explored and are considered potential candidates for treating multiple diseases, including Down’s syndrome, Alzheimer’s disease, Parkinson’s disease and cancer [38]. Here, DYRK1A is linked to Parkinson disease.